These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis. Saito D; Maeshima Y; Nasu T; Yamasaki H; Tanabe K; Sugiyama H; Sonoda H; Sato Y; Makino H Am J Physiol Renal Physiol; 2011 Apr; 300(4):F873-86. PubMed ID: 21228103 [TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Ichinose K; Maeshima Y; Yamamoto Y; Kitayama H; Takazawa Y; Hirokoshi K; Sugiyama H; Yamasaki Y; Eguchi K; Makino H Diabetes; 2005 Oct; 54(10):2891-903. PubMed ID: 16186390 [TBL] [Abstract][Full Text] [Related]
5. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency. Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635 [TBL] [Abstract][Full Text] [Related]
6. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy. Jha JC; Thallas-Bonke V; Banal C; Gray SP; Chow BS; Ramm G; Quaggin SE; Cooper ME; Schmidt HH; Jandeleit-Dahm KA Diabetologia; 2016 Feb; 59(2):379-89. PubMed ID: 26508318 [TBL] [Abstract][Full Text] [Related]
7. Vasohibin-1 has α-tubulin detyrosinating activity in glomerular podocytes. Mifune T; Tanabe K; Nakashima Y; Tanimura S; Sugiyama H; Sato Y; Wada J Biochem Biophys Res Commun; 2022 Apr; 599():93-99. PubMed ID: 35180473 [TBL] [Abstract][Full Text] [Related]
8. Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Nasu T; Maeshima Y; Kinomura M; Hirokoshi-Kawahara K; Tanabe K; Sugiyama H; Sonoda H; Sato Y; Makino H Diabetes; 2009 Oct; 58(10):2365-75. PubMed ID: 19587360 [TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Ziyadeh FN; Wolf G Curr Diabetes Rev; 2008 Feb; 4(1):39-45. PubMed ID: 18220694 [TBL] [Abstract][Full Text] [Related]
10. Thioredoxin-Interacting Protein Deficiency Protects against Diabetic Nephropathy. Shah A; Xia L; Masson EA; Gui C; Momen A; Shikatani EA; Husain M; Quaggin S; John R; Fantus IG J Am Soc Nephrol; 2015 Dec; 26(12):2963-77. PubMed ID: 25855771 [TBL] [Abstract][Full Text] [Related]
11. Tubular overexpression of Gremlin in transgenic mice aggravates renal damage in diabetic nephropathy. Marchant V; Droguett A; Valderrama G; Burgos ME; Carpio D; Kerr B; Ruiz-Ortega M; Egido J; Mezzano S Am J Physiol Renal Physiol; 2015 Sep; 309(6):F559-68. PubMed ID: 26155842 [TBL] [Abstract][Full Text] [Related]
12. Podocyte Glucocorticoid Receptors Are Essential for Glomerular Endothelial Cell Homeostasis in Diabetes Mellitus. Srivastava SP; Zhou H; Setia O; Dardik A; Fernandez-Hernando C; Goodwin J J Am Heart Assoc; 2021 Aug; 10(15):e019437. PubMed ID: 34308664 [TBL] [Abstract][Full Text] [Related]
13. Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice. You H; Gao T; Raup-Konsavage WM; Cooper TK; Bronson SK; Reeves WB; Awad AS Kidney Int; 2017 Mar; 91(3):671-682. PubMed ID: 27914709 [TBL] [Abstract][Full Text] [Related]
14. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Yamamoto Y; Maeshima Y; Kitayama H; Kitamura S; Takazawa Y; Sugiyama H; Yamasaki Y; Makino H Diabetes; 2004 Jul; 53(7):1831-40. PubMed ID: 15220208 [TBL] [Abstract][Full Text] [Related]
15. Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice. Barutta F; Grimaldi S; Franco I; Bellini S; Gambino R; Pinach S; Corbelli A; Bruno G; Rastaldi MP; Aveta T; Hirsch E; Di Marzo V; Gruden G Kidney Int; 2014 Nov; 86(5):979-90. PubMed ID: 24827776 [TBL] [Abstract][Full Text] [Related]
16. Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis. Wang Y; Heilig K; Saunders T; Minto A; Deb DK; Chang A; Brosius F; Monteiro C; Heilig CW Am J Physiol Renal Physiol; 2010 Jul; 299(1):F99-F111. PubMed ID: 20375117 [TBL] [Abstract][Full Text] [Related]
17. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model. Meier M; Park JK; Overheu D; Kirsch T; Lindschau C; Gueler F; Leitges M; Menne J; Haller H Diabetes; 2007 Feb; 56(2):346-54. PubMed ID: 17259378 [TBL] [Abstract][Full Text] [Related]
18. The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Chen HY; Huang XR; Wang W; Li JH; Heuchel RL; Chung AC; Lan HY Diabetes; 2011 Feb; 60(2):590-601. PubMed ID: 20980457 [TBL] [Abstract][Full Text] [Related]
19. MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease. He M; Li Y; Wang L; Guo B; Mei W; Zhu B; Zhang J; Ding Y; Meng B; Zhang L; Xiang L; Dong J; Liu M; Xiang L; Xiang G Diabetologia; 2020 Sep; 63(9):1916-1931. PubMed ID: 32588068 [TBL] [Abstract][Full Text] [Related]
20. Klotho attenuates renal hypertrophy and glomerular injury in Ins2Akita diabetic mice. Kadoya H; Satoh M; Haruna Y; Sasaki T; Kashihara N Clin Exp Nephrol; 2016 Oct; 20(5):671-678. PubMed ID: 26586006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]